Curis begins trial of cancer treatment
Curis Inc. has treated its first patient in a Phase 1b expansion trial for its small molecule drug candidate, CUDC-101, intended to treat advanced head and neck, gastric, breast and liver cancers.
The expansion trial is expected to enroll 40 cancer patients and will measure the safety and tolerability of CUDC-101 as administered five days per week, every other week, as compared to three times per week, with three weeks on and one week off.
The drug candidate is made as an inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor (EGFR) and epidermal growth factor receptor 2 (Her2).
Curis (Nasdaq: CRIS) announced last month that it is lined up to receive a $3 million milestone payment, following its fifth patient treatment in a Phase 1 clinical trial, testing its treatment of lymphoma and advanced solid tumors, led by licensee Debiopharm SA.